home / stock / cltef / cltef quote
Last: | $7.55 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $7.55 |
High: | $0 |
Low: | $0 |
Volume: | 1 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$7.55 | $0 | $7.55 | $0 | $0 | 1 | 04-05-2023 |
$12.08 | $12.08 | $12.08 | $12.08 | $12.08 | 300 | 12-17-2021 |
$9.92 | $8.18 | $9.92 | $9.92 | $8.18 | 7,000 | 12-15-2021 |
$14.69 | $14.69 | $14.69 | $14.69 | $14.69 | 200 | 06-08-2021 |
$14.12 | $14.12 | $14.12 | $14.12 | $14.12 | 100 | 06-07-2021 |
$14.37 | $14.37 | $14.37 | $14.37 | $14.37 | 300 | 06-04-2021 |
$15.64 | $15.64 | $15.64 | $15.64 | $15.64 | 100 | 06-01-2021 |
$14.86 | $14.86 | $14.86 | $14.86 | $14.86 | 100 | 05-31-2021 |
$14.86 | $14.86 | $14.86 | $14.86 | $14.86 | 100 | 05-28-2021 |
$14.85 | $14.85 | $14.85 | $14.85 | $14.85 | 100 | 05-26-2021 |
$15 | $14.92 | $15 | $15 | $14.92 | 200 | 05-24-2021 |
$14.17 | $14.17 | $14.17 | $14.17 | $14.17 | 100 | 05-20-2021 |
$13.69 | $13.68 | $13.69 | $13.69 | $13.68 | 200 | 05-14-2021 |
$13.73 | $13.73 | $13.73 | $13.73 | $13.73 | 100 | 05-13-2021 |
$13.54 | $13.54 | $13.54 | $13.54 | $13.54 | 100 | 05-11-2021 |
$13.87 | $13.87 | $13.87 | $13.87 | $13.87 | 100 | 05-06-2021 |
$13.7 | $13.7 | $13.7 | $13.7 | $13.7 | 100 | 04-23-2021 |
$13.38 | $13.38 | $13.38 | $13.38 | $13.38 | 100 | 04-21-2021 |
$13.37 | $13.37 | $13.37 | $13.37 | $13.37 | 100 | 04-20-2021 |
$13.65 | $13.65 | $13.65 | $13.65 | $13.65 | 100 | 04-16-2021 |
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB - Class B Company Name:
CLTEF Stock Symbol:
OTCMKTS Market:
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) ...
Interim Report Q1, 2021 PR Newswire STOCKHOLM , May 18, 2021 /PRNewswire/ -- Filing of New Drug Application submission to the FDA "Following the positive top line readout of our pivotal Phase 3 trial NefIgArd, which met both the primary and key secondary ...
Calliditas Therapeutics' 2020 Annual Report Published PR Newswire STOCKHOLM , April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's...